Gemfibrozil

Generic Name: Gemfibrozil

Brand Names: Lopid

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂O_₃

CAS Number: 25812-30-0

Unique Ingredient Identifier: Q8X02027X3

Background: Gemfibrozil is a fibric acid agent, similar to clofibrate, used to treat Type IIb, IV, and V hyperlipidemias. Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.

Gemfibrozil was granted FDA approval on 21 December 1981.

Indication: Gemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides (usually above 2000mg/dL), elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions. Gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with Type IIb hyperlipidemia without history or symptoms of coronary heart disease; who do not adequately respond to weight loss, diet, exercise, and other medications; and have low HDL, raised LDL, and raised triglycerides.

Associated Conditions: Coronary Heart Disease (CHD), Fredrickson classification type IV Hyperlipidemia, Fredrickson classification type V Hyperlipidemia

Clinical Trials

Initial Screening of Gemfibrozil as a Novel Treatment for Tobacco Addiction

Phase 2

Completed

Conditions: Nicotine Dependence

Interventions: Drug: Placebo
Drug: Gemfibrozil

First Posted Date: 2013-06-13

Last Posted Date: 2017-04-20

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 28

Registration Number: NCT01876810

Locations: 🇨🇦
Centre of Addiction and Mental Health, Toronto, Ontario, Canada
🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: LY2409021
Drug: Gemfibrozil
Drug: Ketoconazole
Drug: Clarithromycin

First Posted Date: 2013-04-19

Last Posted Date: 2019-03-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 30

Registration Number: NCT01836198

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States

A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects

Phase 1

Completed

Conditions: Drug-Drug Interaction (DDI)
Healthy Subjects

Interventions: Drug: ASP3652
Drug: Gemfibrozil
Drug: Repaglinide

First Posted Date: 2013-02-22

Last Posted Date: 2013-02-22

Lead Sponsor: Astellas Pharma Europe B.V.

Target Recruit Count: 48

Registration Number: NCT01797198

Locations: 🇬🇧
PAREXEL Early Phase Clinical Unit, Harrow, United Kingdom

A Study of Evacetrapib in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Evacetrapib
Drug: Gemfibrozil

First Posted Date: 2012-11-29

Last Posted Date: 2018-10-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT01736254

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States